Creative Touch Permanent Makeup and Aesthetics

Vitreoscilla filiformis lysate is the ingredient that gives the Microbiome-Targeted Skincare category its strongest clinical credibility – the only single postbiotic ingredient in topical skincare with a double-blind RCT demonstrating clinical outcomes in atopic dermatitis, a characterised intracellular signalling mechanism connecting its cell wall components to hBD-2 induction in keratinocytes, and a product-level commercial anchor ( La Roche-Posay Lipikar programme) that practitioners and clients can access directly in the UK.

What makes V. filiformis mechanistically distinctive is precision. It delivers TLR2 agonism – the same innate immune receptor activation that S. epidermidis provides continuously in healthy skin – without delivering live bacteria, without producing LPS-mediated TLR4 inflammatory activation (despite being gram-negative, its LPS fraction is effectively inactive in the commercial lysate preparation), and without the formulation, stability, and UK regulatory challenges that live probiotic cosmetics face. The lysate is the active component of the organism without the organism itself. It provides the TLR2 signal that the depleted commensal ecosystem of AD skin is failing to generate, delivered consistently with every product application regardless of the client’s skin microbiome state.

The spa water-grown variant (LRP-VFB, developed by La Roche-Posay using thermal spring water mineral enrichment) amplifies hBD-2 induction 4–6-fold over the standard lysate – a formulation refinement with mechanistic explanation: the mineral-enriched growth medium produces a V. filiformis biomass with altered cell wall composition that generates stronger TLR2 agonist activity per unit lysate applied. ^[1]

Vitreoscilla filiformis is a non-pathogenic gram-negative aerobic bacterium of the Neisseriaceae family, naturally occurring in aquatic environments including thermal spring water. It is filamentous – growing in long thread-like chains rather than individual cocci or rods – and has been cultivated for cosmetic use since the mid-2000s, when research groups at La Roche-Posay identified its TLR2-activating properties and developed the heat-inactivated lysate form for topical application. ^[3]

Its gram-negative cell wall structure – outer membrane containing lipopolysaccharide (LPS) and lipoproteins, inner peptidoglycan layer – is the source of its TLR2 agonist activity. Gram-negative bacterial LPS is conventionally associated with TLR4 activation and the potent pro-inflammatory NF-κB/ IL-6/ TNF-α cascade that TLR4 drives. V. filiformis is unusual among gram-negative organisms in that its LPS fraction – in the heat-inactivated lysate form used cosmetically – does not produce significant TLR4 activation in keratinocyte models. The TLR2 agonism is mediated instead by its lipoprotein and lipoteichoic acid-equivalent outer membrane components, which activate the TLR2/TLR6 heterodimer. This TLR4 inactivity is what makes V. filiformis lysate tolerable as a topical ingredient in inflamed skin – where TLR4 hyperactivation would compound rather than address the inflammatory environment. ^[3]

The TLR2/PKCζ/hBD-2 mechanism

The intracellular signalling pathway from V. filiformis lysate to hBD-2 induction in keratinocytes was characterised in the series of studies published between 2008 and 2013 that established the mechanistic rationale for its cosmetic use. The pathway diverges from the classical TLR2/NF-κB route in one important way – PKCζ involvement – that has functional significance for the cytokine profile produced: ^[3]

1. TLR2/TLR6 ligation by V. filiformis lipoprotein components → MyD88 adaptor protein recruitment → IRAK4/TRAF6 signalling complex assembly
2. PKCζ (Protein Kinase C zeta) activation – an atypical PKC isoform that selectively activates NF-κB through the IKKβ/IκB-α phosphorylation route without concomitant activation of the MAPK/AP-1 pathway to the same degree as classical TLR2/MyD88 → TRAF6 → TAK1 → NF-κB signalling
3. NF-κB nuclear translocation driving transcription of: DEFB4 (hBD-2) – the primary antimicrobial output; S100A7 (psoriasin – antimicrobial peptide with additional S. aureus inhibitory activity); SOD2 (manganese superoxide dismutase – oxidative stress protection in keratinocytes); CCL20 (dendritic cell chemokine – innate immune cell recruitment); IL-8 (neutrophil chemoattractant) ^[3]

The PKCζ-mediated route is significant because it produces a more targeted transcriptional output than broad NF-κB activation would generate – driving the AMP-inductive and cellular-protective gene set (hBD-2, S100A7, SOD2) without proportionately upregulating the pro-inflammatory cytokine set (IL-1β, IL-6, TNF-α) that full TLR2 → TRAF6 → TAK1 signalling produces at higher stimulus intensities. This selectivity is the mechanistic reason why V. filiformis lysate can be applied to inflamed AD skin – which is already producing excess inflammatory cytokines – without further amplifying the Th2 environment. It is adding the AMP-inductive TLR2 signal selectively, not re-inflaming the tissue. ^[1]

The spa water-grown variant: LRP-VFB

The standard V. filiformis biomass (VFB) is grown in conventional culture medium. The La Roche-Posay variant (LRP-VFB) is grown in La Roche-Posay thermal spring water – selenium-rich, silica-containing, characteristically low-mineralisation water from the La Roche-Posay thermal source. The mineral profile of the growth medium alters the cell wall composition of the organism – specifically the fatty acid profile of its outer membrane lipoproteins – producing a lysate with measurably higher TLR2/PKCζ agonist activity per unit weight than standard VFB. ^[3]

The 2013 PMC study (Gueniche et al., Exp Dermatol) directly compared standard VFB and LRP-VFB in keratinocyte models at the same concentration: LRP-VFB produced 4–6-fold greater hBD-2 induction than VFB, with proportionate increases in S100A7 and SOD2 expression. The study also demonstrated that LRP-VFB produced greater S. aureus inhibition ex vivo at equivalent lysate concentrations – a directly functional consequence of the amplified hBD-2/S100A7 output. ^[3]

The LRP-VFB variant is incorporated into the La Roche-Posay Lipikar product line – the commercial application of this research – and is the specific form for which the RCT clinical data was generated. Products using generic V. filiformis extract from other suppliers may use standard VFB with lower hBD-2 induction activity; the INCI name does not distinguish between VFB and LRP-VFB.

Clinical evidence – the RCT

The clinical evidence base for V. filiformis lysate in atopic dermatitis rests on a 75-patient double-blind, randomised, placebo-controlled trial conducted by Gueniche and colleagues, with results published in peer-reviewed form (full study parameters available: NCT00509535 on ClinicalTrials.gov). ^[1]

Study design: 75 adults with moderate atopic dermatitis; 30-day treatment period; V. filiformis lysate emollient versus vehicle control (placebo emollient without active lysate); twice-daily application; assessor-blinded endpoint evaluation.

Primary endpoints and outcomes at 30 days: SCORAD (Scoring Atopic Dermatitis composite severity index): statistically significant reduction in active arm versus placebo TEWL (Transepidermal water loss, Tewameter measurement): significant improvement – reduced TEWL indicating barrier function improvement Pruritus score (visual analogue scale): significant reduction in itch intensity Sleep quality (patient-reported): significant improvement – reflecting reduced nocturnal itch * S. aureus colonisation density (swab quantification): significant reduction in lesional S. aureus counts in active arm versus placebo [academia]

The S. aureus colonisation endpoint is the most mechanistically informative result – it directly confirms that the TLR2/hBD-2/S100A7 AMP induction produced by the lysate translates into reduced pathogen burden at the skin surface in vivo, not just in keratinocyte culture models. The mechanism predicted this outcome. The RCT confirmed it.

Evidence calibration: This is a single 75-patient RCT with industry involvement (La Roche-Posay research affiliation). It is the most robust clinical evidence available for any single postbiotic ingredient in topical skincare, and it substantially exceeds the evidence tier of most microbiome-targeted ingredients in commercial use. It should not be represented as equivalent to the multi-thousand-patient pivotal trials supporting licensed pharmaceutical products – but for a cosmetic ingredient with a characterised molecular mechanism, it is an unusually strong evidence package. clinicaltrials

V. filiformis in the AD microbiome context

The mechanistic rationale for V. filiformis lysate in AD fits precisely into the microbiome deficit that the condition creates. In AD lesional skin, S. epidermidis diversity is reduced, and the continuous TLR2/hBD-2 induction circuit that healthy commensal colonisation provides is therefore underperforming. V. filiformis lysate does not replace S. epidermidis – it replaces the TLR2 induction signal that S. epidermidis was providing. Every application delivers a TLR2 agonist that drives hBD-2 transcription regardless of what the current microbial community looks like. This makes V. filiformis uniquely useful precisely in the clinical context where the microbiome is most depleted – when S. epidermidis diversity is too low to maintain adequate TLR2 signalling naturally, the lysate substitutes for the missing commensal signal with each product application. ^[5]

The combination with inulin prebiotic is therefore more than formulation convenience. Inulin supports S. epidermidis density recovery over time – a slow ecological restoration that takes weeks to months. V. filiformis lysate provides immediate TLR2/hBD-2 activation at every application while the ecology recovers. Together they address the same deficit through different timescales: the postbiotic acts immediately; the prebiotic acts sustainably. The synbiotic formulation delivers both. scirp

V. filiformis beyond atopic dermatitis

Post-procedure skin. The post-procedural application of V. filiformis lysate is mechanistically well-supported even though clinical trial data in this specific context does not exist. At barrier disruption sites – after microneedling, fractional laser, ablative procedures – the skin’s commensal ecosystem is transiently disturbed, S. aureus opportunistic colonisation risk is elevated, and the hBD-2-mediated antimicrobial defence that TLR2/hBD-2 provides is most needed. V. filiformis lysate applied in a post-procedure formulation delivers TLR2/hBD-2 activation from the first application – before the microbiome has had time to re-establish – supporting antimicrobial defence in the window when the barrier is most vulnerable. The caveat: in the immediate post-procedure period (first 24 hours on actively disrupted skin), the TLR2/NF-κB/IL-8 output of the lysate may generate mild erythema or sensitivity on highly reactive post-procedure skin. Introduction from 24–48 hours post-procedure, when re-epithelialisation has begun, is the appropriate timing. ^[3]

Rosacea – nuanced application. V. filiformis lysate’s TLR2/hBD-2 induction route does not activate the KLK5/ LL-37 pathway – it drives beta-defensin production, not cathelicidin production. This distinction makes it potentially appropriate in rosacea-affected skin where increasing hBD-2 antimicrobial activity is desirable (reducing S. aureus and Demodex-associated opportunistic colonisation) without risking further amplification of the LL-37 excess that is driving the inflammatory cascade. The practitioner applying this ingredient in rosacea presentations should understand the pathway clearly enough to make this distinction – it is not a general “anti-inflammatory” ingredient, and TLR2 activation in the wrong context could theoretically contribute to NF-κB-driven inflammation. The hBD-2 selective output of PKCζ-mediated signalling is the mechanistic basis for its tolerability in rosacea; the distinction from full TLR2 → TAK1 → broad NF-κB inflammatory activation is the relevant nuance. ^[4]